NuView Life Sciences is transforming cancer diagnostics and treatment with its pioneering NV-VPAC1™ platform. This first-of-its-kind technology integrates in vitro diagnostics, in vivo imaging, and precision-targeted therapy, offering a seamless solution for earlier detection, more personalized treatments, and reduced healthcare costs. At its core is a non-invasive liquid biopsy test that promises to redefine how cancers are detected and managed, while the broader platform unlocks the full potential of theranostics in precision oncology.
Moe: What makes NuView’s in vitro liquid biopsy test a breakthrough in cancer diagnostics?
Paul Crowe: Our in vitro liquid biopsy test is a game-changer in early cancer detection. It’s a non-invasive, urine-based diagnostic that offers exceptional sensitivity and specificity, addressing key challenges like false positives and unnecessary biopsies. By detecting cancers such as prostate, bladder, and breast at early stages, the test empowers physicians with rapid, reliable results, enabling better treatment decisions. Beyond its diagnostic performance, the test is scalable, economical, and compatible with various liquid specimens, including blood and saliva, making it accessible to a global patient population. With the IVD market projected to grow from $80.71 billion in 2024 to $117.6 billion by 2032, we are poised to capture significant opportunities in multi-cancer detection.
Moe: How does NV-VPAC1 integrate diagnostics, therapy, and personalized care to advance cancer treatment?
Paul Crowe: NV-VPAC1 bridges the gap between diagnostics and therapy while enabling a highly personalized approach to cancer care. Using Cu-64 for imaging, our technology identifies malignant tissue with high specificity by targeting VPAC1 receptors, which are overexpressed in cancers like prostate, bladder, brain, and more. This allows us to detect cancer even before histologic changes occur, giving patients the best chance at successful treatment. For therapy, Cu-67 provides sustained radiation directly to cancer cells, minimizing damage to healthy tissue and reducing the need for frequent dosing. By tailoring diagnostics and treatment to each patient’s unique cancer profile, we’re creating a platform that treats the individual, not just the disease. This integration significantly reduces patient burden and improves outcomes, aligning with the broader push for personalized medicine.
Moe: What sets NuView apart from its competitors in the oncology space?
Paul Crowe: NuView’s platform uniquely integrates in vitro diagnostics, in vivo imaging, and theranostics into a single, cohesive system. This comprehensive approach provides unparalleled precision, enabling earlier detection and more personalized treatment plans. Our receptor specificity is another key differentiator. Unlike competitors whose receptors lack the precision needed for broad clinical applications, our VPAC1 receptor targeting delivers unmatched accuracy and reliability, addressing multiple cancer types while reducing false positives and unnecessary follow-ups. Our robust intellectual property portfolio also ensures that NuView remains at the forefront of innovation, delivering long-term growth and sustained impact.
Moe: How is NuView scaling its technologies and expanding globally?
Paul Crowe: We are scaling our operations through strategic partnerships and clinical trials. One of our key initiatives is collaborating with the VA healthcare system to validate our prostate cancer diagnostic. This partnership has the potential to improve access to non-invasive diagnostics for veterans significantly. In early 2025, we’ll begin clinical trials in Mexico City as part of our LATAM expansion. These trials will leverage AI-enhanced microscopy to refine diagnostic accuracy and establish our platform’s efficacy in a broader global context. Our regulatory milestones are also on track, with prostate cancer diagnostic trials slated for Q1 2025. This marks a significant step toward bringing NV-VPAC1 to market and demonstrating its value across diverse healthcare systems.
Moe: What is NuView’s long-term vision for its platform?
Paul Crowe: At NuView, our vision is to redefine precision oncology with a fully integrated platform that addresses every stage of cancer care—from early detection to targeted therapy. Our tagline, “Pioneering the First Lab and Theranostic Platform,” reflects this mission. We are committed to delivering transformative technologies that improve outcomes, reduce costs, and provide a more patient-centered approach to treatment. As we continue to grow, I’m confident that NV-VPAC1 will set a new benchmark in cancer care and establish NuView as a leader in this space.
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
